【摘要】 为了观察吉西他滨联合卡培他滨治疗晚期肝癌的临床疗效及不良反应,选择无法手术及介入治疗的晚期原发性肝癌患者26例,给予吉西他滨1000mg/m2,持续静脉滴入30min,d1、d8;卡培他滨1000mg/m2,口服,2次/d,d1～d14,21d为1个周期,入组的每例患者至少接受2个周期的治疗。结果PR11例(42.3%),NC6例(23.1%),PD9例(34.6%),客观有效率(PR+CR)为42.3%(11/26);疾病控制率(PR+CR+SD)为65.4%(17/26)。不良反应主要有血液学毒性(主要为中性粒细胞减少和血小板减少)和手足综合征,多为1～2度,耐受性良好。中位生存期(MST)6.8个月,1年生存率38.5%。初步研究结果提示,吉西他滨联合卡培他滨治疗晚期肝癌的疗效及患者依从性好,用药方便,费用相对低廉,值得临床进一步研究。更多还原

【Abstract】 The objective of this study was to detect the therapeutic efficacy and side reactions of Gemcitabine combined with Capecitabine in the treatment of advanced hepatocellular carcinoma.Twenty-six patients with advanced hepatocellular carcinoma which could not be surgical resection and interventional therapy were involved in this study.Gemcitabine 1 000 mg/m2,intravenous drip 30 min,d1,d8;capecitabine 1 000 mg/m2,twice a day orally,d1-d14,21 d as one cycle.Each patients received at least every two cycles of treatment.PR 11 cases (42.3%);NC 6 cases (23.1%),PD 9 cases (34.6%);RR(PR+CR) 42.3%;DCR(PR+CR+SD)65.4%.Main side effects were hematologic toxicity (mainly neutropenia and thrombocytopenia),and hand-foot syndrome,mostly 1 to 2 degrees,well-tolerated.The median survival time (MST) was 6.8 months and 1 year survival rate was 38.5%.In conclusion,this program has a good curative effect,and patient compliance is good,medication convenience,cost is relatively low,so it is worthy of further clinical studies.更多还原